BridgeMD
Tests treatment safety and results for Hypovolemic Shock
Official title A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients
ClinicalTrials.gov ID: NCT05956418
What this study is testing
What is Centhaquine?
Centhaquine is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for hypovolemic shock.
Also referred to as LYFAQUIN™, Centhaquine Citrate.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective, multi-centric, open-labeled, phase-IV clinical study to evaluate the safety and efficacy of centhaquine citrate (LYFAQUIN™), a first-in-class drug for treating hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. Centhaquine has been found to be an effective resuscitative agent in rat, rabbit, and swine models of hemorrhagic shock.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult hypovolemic shock patients aged 18 years or older admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation...
You likely can't join if
- Development of any other terminal illness not associated with hypovolemic shock during the study duration.
- Patient with altered consciousness not due to hypovolemic shock and comatose patient. Known pregnancy.
- Cardiopulmonary resuscitation (CPR) before enrollment.
- Presence of a do not resuscitate order.
- Patient is participating in another treatment study.
- Patients with systemic diseases which were already present before having trauma, such as sepsis, cancer, chronic renal failure, liver failure...
The study team makes the final eligibility decision.
Where it's taking place
- Nellore, Andhra Pradesh, India
- Raipur, Chhattisgarh, India
- Vadodara, Gujarat, India
- Nagpur, Maharashtra, India
- Amritsar, Punjab, India
- Ludhiana, Punjab, India
- Kota, Rajasthan, India
- Coimbatore, Tamil Nadu, India
- Agra, Uttar Pradesh, India
- Jhānsi, Uttar Pradesh, India
- Kanpur, Uttar Pradesh, India
- Varanasi, Uttar Pradesh, India
- Kolkata, West Bengal, India
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nellore, Andhra Pradesh, India; Raipur, Chhattisgarh, India; Vadodara, Gujarat, India; Nagpur, Maharashtra, India; Amritsar, Punjab, India; Ludhiana, Punjab, India and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.